3C-DFM

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

3C-DFM, also known as 4-(2,2-difluoromethoxy)-3,5-dimethoxyamphetamine or as or as α-methyldifluoromescaline (3C-difluoromescaline), is a serotonin receptor modulator of the phenethylamine and 3C families. It is the amphetamine (α-methyl) derivative of the psychedelic drug difluoromescaline (DFM). The properties and effects of 3C-DFM in humans are unknown. The drug shows affinity for the serotonin 5-HT 2 receptors and is known to act as an agonist of the serotonin 5-HT 2A and 5-HT 2B receptors. 3C-DFM was first described in the scientific literature by Daniel Trachsel by 2012. It is a controlled substance in Ukraine. The drug is also a controlled substance in Canada under phenethylamine blanket-ban language.

3C-DFM, also known as 4-(2,2-difluoromethoxy)-3,5-dimethoxyamphetamine or as or as α-methyldifluoromescaline (3C-difluoromescaline), is a serotonin receptor modulator of the phenethylamine and 3C families. It is the amphetamine (α-methyl) derivative of the psychedelic drug difluoromescaline (DFM). The properties and effects of 3C-DFM in humans are unknown. The drug shows affinity for the serotonin 5-HT 2 receptors and is known to act as an agonist of the serotonin 5-HT 2A and 5-HT 2B receptors. 3C-DFM was first described in the scientific literature by Daniel Trachsel by 2012. It is a controlled substance in Ukraine. The drug is also a controlled substance in Canada under phenethylamine blanket-ban language.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1366870073 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.